Abstract:Background Islet transplantation is used therapeutically in a minority of patients with type 1 diabetes (T1D). However, successful outcomes are hampered by early islet β-cell loss caused by immune rejection and autoimmunity. Recent studies have demonstrated that mesenchymal stromal cells can enhance islet function both in vitro and in vivo by secreting ligands that activate islet G-protein coupled receptors (GPCRs). Stromal cell-derived factor 1 (SDF-1) is an MSC-secreted GPCR ligand, whereas the suppressor of cytokine signaling 3 (SOCS3) is a negative regulator of STAT3-activating cytokines. Here, we determined whether improvement in islet function mediated by exogenous SDF-1 is impaired by SOCS3 in experimental models of T1D. Methods Isolated islets were cultured for 48 h with SDF-1. Cytokine-induced apoptosis was measured immediately. Islets from Socs3 −/− mice were pre-cultured with exogenous SDF-1 and transplanted underneath the kidney capsule of C57BL/6 mice with streptozotocin-induced diabetes. Blood glucose levels were monitored for 28 days. AMD3100, an antagonist of the SDF-1 ligand CXCR4, was administered subcutaneously to islet transplanted mice to inhibit CXCR4 before and after transplantation. Results SDF-1 protected islet cells from cytokine-induced apoptosis in vitro. SOCS3-knockout (KO) islets pretreated with SDF-1 were effective in reducing blood glucose in non-obese diabetic mice in vivo. We found that SDF-1 elicits localized immunosuppression in transplanted SOCS3-KO islets. Immunomodulation was observed when SOCS-KO islets were preconditioned with SDF-1. Gene expression and flow cytometric analyses revealed significantly decreased immune cell infiltration, inflammatory cytokines, and concomitant increases in FOXP3 + regulatory T cells, alternatively activated M2 macrophages, and dendritic cell phenotypes. Administration of AMD3100 impaired the SDF-1-mediated improvement in SOCS3-KO islet function and local immune suppression. Conclusion SDF-1 improves the function of islet grafts in autoimmune diabetes through regulation by CXCR4; however, the presence of SOCS3 reverses the protective effect of SDF-1 on islet grafts. These data reveal a molecular pathway that can elicit localized immunosuppression and delay graft destruction in transplanted islets.

Retracted: MicroRNA‐30d Preserves Pancreatic Islet Β‐cell Function Through Negative Regulation of the JNK Signaling Pathway Via SOCS3 in Mice with Streptozotocin‐induced Diabetes Mellitus

MicroRNA-185 targets SOCS3 to inhibit beta-cell dysfunction in diabetes

MicroRNA-223 is Essential for Maintaining Functional Β-Cell Mass During Diabetes Through Inhibiting Both FOXO1 and SOX6 Pathways

Differentially Expressed MicroRNA-483 Confers Distinct Functions in Pancreatic Β- and Α-Cells

MicroRNA-17-92 Regulates Beta-Cell Restoration after Streptozotocin Treatment.

MiR-30a Targets IL-1α and Regulates Islet Functions As an Inflammation Buffer and Response Factor.

Mir-101A and Mir-30B Contribute to Inflammatory Cytokine-Mediated Β-Cell Dysfunction

SOCS3 Inhibits the Mesenchymal Stromal Cell Secretory Factor SDF-1-mediated Improvement of Islet Function in Non-Obese Diabetic Mice.

Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes

MiR-17-5p Inhibits TXNIP/NLRP3 Inflammasome Pathway and Suppresses Pancreatic β-Cell Pyroptosis in Diabetic Mice

Smad3 deficiency promotes beta cell proliferation and function in db/db mice via restoring Pax6 expression

Cross-talks Between Micrornas and Mrnas in Pancreatic Tissues of Streptozotocin-Induced Type 1 Diabetic Mice

Mechanism of Inhibition of PancreaticβCell Apoptosis by MicroRNA-32 in Type 2 Diabetes of Mice

Expression of miRNA-29 in Pancreatic β Cells Promotes Inflammation and Diabetes via TRAF3

Microrna-503 Contribute to Pancreatic Beta Cell Dysfunction by Targeting the Mtor Pathway in Gestational Diabetes Mellitus.

Repressing miR-23a promotes the transdifferentiation of pancreatic α cells to β cells via negatively regulating the expression of SDF-1α

Effects of miR-22-3p targeted regulation of Socs3 on the hepatic insulin resistance in mice with gestational diabetes mellitus

MicroRNA Networks in Pancreatic Islet Cells: Normal Function and Type 2 Diabetes

Mirna-30e Regulates Abnormal Differentiation of Small Intestinal Epithelial Cells in Diabetic Mice by Downregulating Dll4 Expression

miR-210-3p Impairs Pancreatic ?-Cell Function by Targeting Dtx1 in Gestational Diabetes Mellitus

Mir-192 Is Upregulated In T1dm, Regulates Pancreatic -Cell Development And Inhibits Insulin Secretion Through Suppressing Glp-1 Expression